Preimplantation factor (PIF) is a peptide secreted by viable mammalian embryos. Moreover, it can be detected in the circulation of pregnant women. Recently, it was shown that PIF promotes invasion in trophoblast cell lines in vitro. Successful human embryo implantation depends on a deep and highly controlled invasion of extravillous trophoblast (EVT) in the maternal endometrium. Trophoblast invasion is regulated in part by matrix metalloproteinase (MMP) activity and integrin expression. The present study demonstrates the presence of PIF in early pregnancy and characterizes its effects on primary human trophoblast invasion. At the fetomaternal interface, intense PIF labeling by immunohistochemistry was present during early gestation in villous trophoblasts and EVTs. A decrease of labeling was observed at term. Furthermore, PIF significantly promoted invasion of human EVT isolated from first-trimester placenta. The proinvasive regulatory effect of PIF in EVT was associated with 1) increased MMP9 activity and 2) reduced tissue inhibitor of metalloproteinase-1 (TIMP1) mRNA expression. PIF also regulated alpha v and alpha 1 integrin mRNA expressions. Last, the proinvasive effect of PIF appeared to be mediated by the mitogenactivated protein kinase (MAPK), phosphoinositide-3-kinase (PI3K), and Janus-kinase signal transducer and activator of transcription (JAK-STAT) signaling pathways. In summary, this work describes the direct, positive effect of PIF on the control of human trophoblastic cell invasion by modulation of MMP/TIMP balance and integrin expression. Moreover, these results suggest that PIF is involved in pathological pregnancies characterized by insufficient or excessive trophoblast invasion.
INTRODUCTION
Embryo implantation and placentation are critical steps in the establishment of successful pregnancy. Trophoblast cells exert an essential role in placental development. These cells differentiate into villous trophoblasts (VTs) and extravillous trophoblasts (EVTs). Implantation requires a number of distinct cellular events, including effective invasion of the endometrium by the EVT. This invasion is a multistep process involving attachment of the EVT to the extracellular matrix (ECM) components, degradation of decidual and endothelial ECM, and migration through the eroded connective tissue [1, 2] . For this process, the action of proteases, particularly the matrix metalloproteinases (MMPs) 2 and 9, is very important [3] . The MMPs are secreted in a latent form and their activities are regulated by local concentration of the physiological tissue inhibitors of metalloproteinases (TIMPs) 1 and 2, which bind to MMPs with a 1:1 stoichiometry [4] . Thus, the balance between MMPs and TIMPs at the invasive site is critical. Moreover, EVTs secrete large amounts of highly heterogeneous ECM proteins during acquisition of invasive capacity. These proteins are regulated by ECM receptors, including cadherins, gap junction molecules, and integrins (ITGs) [2] . The ITGs are heterodimeric receptors that mediate cell-ECM binding. Each heterodimer comprises an alpha (a) subunit and a beta (b) subunit. When trophoblasts differentiate into EVTs, a down-regulation of a6b4 ITG and an up-regulation of a5b1, a1b1, and avb3 ITGs are observed. This switch in ITG expression is known to be related to acquisition of the invasive phenotype [5, 6] .
Trophoblast invasion also depends on an orchestrated balance between proinvasive and anti-invasive factors under the control of continuous fetomaternal dialogue. Various regulatory factors (such as growth factors, cytokines, and hormones) modulate EVT invasion in an autocrine and paracrine fashion [7] [8] [9] [10] . For example, adiponectin (an adipokine secreted locally by the endometrium) significantly promotes the human EVT invasion by modulating the MMP/ TIMP balance [11] . These regulatory factors lead to the activation of critical signaling cascades such as mitogenactivated protein kinase (MAPK), focal adhesion kinase (FAK), the phosphoinositide-3-kinase (PI3K)-Akt pathway, Wingless (Wnt) signaling, or the Janus-kinase signal transducer and activator of transcription (JAK-STAT). These multiple pathways are known to control a wide range of biological processes including proliferation, differentiation, migration, invasion, and apoptosis [12] . Overall, the mechanisms underlying trophoblast invasion are complex and not yet clearly elucidated.
Herein, we focused on preimplantation factor (PIF) and its role in successful viable pregnancy. This factor is an embryoderived peptide secreted by viable mammalian embryos as early as two-cell stage. Conversely, PIF is absent in the culture media from nonviable mammalian embryos [13, 14] . Sera of patients with recurrent pregnancy loss (RPL) can be toxic for embryo development [15, 16] . PIF rescued embryos cultured in the presence of serum derived from RPL patients, preventing toxicity and suggesting a direct autotrophic effect of PIF [17, 18] . A very recent study has shown that PIF directly interacts with protein targets like protein-di-isomerase/thioredoxin and heat shock proteins (HSPs), reinforcing its protective role particularly against oxidative stress [19] . PIF is also present in the human placenta and the maternal circulation during pregnancy until term [20] [21] [22] . Furthermore, PIF influences the maternal immune system by increasing peripheral tolerance [20] . Moreover, in the endometrium, PIF enhances embryo adhesion by creating a beneficial proreceptive, proinflammatory environment and by controlling adaptive apoptotic processes [23, 24] . PIF's capacities to modulate inflammatory and immune features, both processes required for embryo implantation, have been documented in various studies [25] [26] [27] [28] .
In the present study, our premise is that PIF might regulate human trophoblast invasive capacities. A previous in vitro study showed that PIF could increase the invasive ability of a transformed trophoblast cell line HTR-8/SVneo [29] . Therefore, we wondered whether PIF could regulate invasion of primary human EVT isolated from first-trimester placenta. We examined PIF effects on EVT invasion and characterized the molecular mechanisms underlying PIF biological effects. These data are likely to be highly relevant for understanding embryo-maternal dialogue at early stages of pregnancy.
MATERIALS AND METHODS

Materials
Synthetic PIF (purity documented by HPLC and mass spectrometry: .95%) was produced by Biosynthesis. PIF*-related reagents were purchased from BioIncept. Dulbecco modified Eagle medium (DMEM)-Ham Nutrient Mix F12 (DMEM/F12), penicillin-streptomycin, HEPES, MgSO 4 , dimethyl sulfoxide (DMSO), bovine serum albumin (BSA), Percoll, and DNase type IV were purchased from Sigma Chemical Co. Matrigel was obtained from BD Biosciences and trypsin was purchased from Difco Laboratories. Hanks balanced salt solution (HBSS) and fetal calf serum (FCS) were purchased from Gibco (Invitrogen). Superscript II RNase H-RT and primers were purchased from Invitrogen and RNA guard was obtained from Pharmacia Biotechnology. The Nucleospin RNA kit was obtained from Macherey-Nagel. The GelRed acid nucleic gel stain was purchased from Interchim. The mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase (MEK) inhibitor UO126 was purchased from Promega, the PI3K inhibitor LY294002 was obtained from Merck Chemical, and the JAK/STAT inhibitor AG490 was obtained from Calbiochem.
Tissue Collection
This study was approved by the local ethical committee (Comité Consultatif de Protection des Personnes dans la Recherche Médicale, reference protocol 01-78) and informed consent was obtained from each donor before clinical sampling. First-trimester human placentas (4-12 wk of gestation [WG] ) were obtained from legal elective abortions. The 4-7-WG placental tissues were obtained after medical abortion and the 8-12-WG placental tissues were obtained after surgical abortion. Third-trimester human placentas were collected from cesarean sections before the onset of labor.
EVT Cell Isolation
First-trimester human placental tissues (4-7 WG) were obtained from healthy, pregnant women aged 20 to 39 yr. The EVT cells were prepared from tips of placental terminal villi, as previously described [30] . Briefly, terminal villi were incubated in HBSS containing 0.125% trypsin, 4.2 mM MgSO 4 , 25 mM HEPES, 50 U/ml DNase (type IV) for 30 min at 378C in the absence of agitation. After tissue sedimentation, the supernatant was filtered through a 100-lm nylon screen and centrifuged at 200 3 g for 10 min. Cells were washed twice and then filtered through a 40-lm nylon screen. The cell suspension was layered over a discontinuous Percoll gradient and centrifuged for 25 min at 1000 3 g. The EVT-containing layer (corresponding to 40%-45% Percoll) was washed twice in HBSS supplemented with 10% FCS. Cells were seeded onto 5 mg/ml Matrigel-coated dishes containing F12/DMEM with 1% FCS, penicillin (100 U/ml), and streptomycin (100 lg/ml) and were then maintained at 378C in a 5% CO 2 , 95% air atmosphere.
EVT Cell Characterization
Purified EVT cells were characterized using immunocytochemistry, flow cytometry, and RT-PCR analysis.
Immunocytochemistry. After 48 h of culture, EVTs were fixed in 100% methanol for 20 min at À208C. Cells were incubated with 3% immunoglobulin G (IgG)-free HBSS-BSA for 30 min to reduce nonspecific binding. Cytokeratin 7 (Dako) and HLA-G (4H84, Santa Cruz Biotechnology) were used in order to characterize cytotrophoblasts (CTs) and EVTs, respectively. These primary antibodies diluted in HBSS with 1% IgG-free BSA were added for 1 h at room temperature. Cells were washed in 1% IgG-free HBSS-BSA, then incubated with a secondary anti-mouse IgG antibody, Alexa Fluor 488 conjugated antimouse IgG antibody (Molecular Probes, Thermo Fisher Scientific Inc.) for CK7 detection or rhodamin-conjugated anti-mouse IgG antibody (Jackson ImmunoResearch) for HLA-G detection during 45 min. Negative control were performed by incubating the cells in the absence of primary antibody. Cell nuclei were counterstained with Hoechst 33258 (Sigma-Aldrich). EVT immunostaining was observed using an inverted laser scanning confocal microscope (Leica white light laser TCS SP8-X; Leica Microsystems).
Flow cytometry analysis. EVT suspensions were fixed in 4% paraformaldehyde for 30 min at room temperature, washed in 1% HBSS-BSA, and incubated with 3% IgG-free HBSS-BSA for 30 min at 48C. Then cells were incubated with CK7 or HLA-G antibodies for 1 h at 48C. Cells were centrifuged at 300 3 g for 10 min and washed twice. Samples were incubated with Alexa Fluor 488 conjugated anti-mouse IgG antibody for 30 min at 48C. EVTs were washed in 1% HBSS-BSA and analyzed in a Fortessa flow cytometer (BD LSRFortessa; Becton Dickinson).
Quantitative RT-PCR. The expression of EVT marker was confirmed by RT-PCR using specific primers for HLA-G transcripts, as described in [31] .
First-Trimester Villous Explant Culture
Pieces of villous tissue 2 3 2 mm in diameter from different first-trimester placentas were dissected and cultured on collagen-I-coated 12-well plates. Placental samples were left cultured for 2 h at 378C under 5% CO 2 , 95% air atmosphere prior to addition of DMEM/F12 supplemented with 1% FCS, penicillin (100 U/ml), and streptomycin (100 lg/ml).
Immunohistochemistry
Placental tissue samples from healthy pregnant women aged 20 to 39 yr were collected at 4, 8, 12, 32, 34, and 36 WG. Placentas were processed as previously described [32] . The slides were rinsed in the buffer supplied by the manufacturer (Ventana Medical Systems) and then incubated with the primary anti-PIF monoclonal antibody (1:150; GenWay) for 40 min at 378C. Mouse monoclonal anti-cytokeratin pan-antibody (KL1; 1:120; Dako Cytomaton) was applied for 20 min at room temperature in order to characterize VT and EVT [33, 34] . For EVTs, rabbit monoclonal anti-HER-2/neu antibody (800-2996; anti-c-erbB2; Ventana Medical Systems) was applied for 16 min [35] . To measure CT proliferation, anti-Ki67 antibody (MIB-1/M7240; 1:60; Dako Cytomaton) was applied for 28 min. After washing, slides were incubated with biotinylated secondary antibodies for 8 min at room temperature. The results were visualized via incubation using a 3,3 0 -diaminobenzidine detection kit (Ventana Medical Systems) for 8 min at room temperature. The slides were then counterstained with hematoxylin for 1 min. As negative controls, sections were processed in the absence of primary antibody, in the presence of nonimmune immunoglobulin, or in the presence of primary antibody neutralized by an excess of synthetic PIF peptide. Digital images were acquired using the Aperio ScanScope AT2 Slide Scanner (Leica Biosystems).
MOINDJIE ET AL.
VT nuclei labeled positively for Ki-67 were counted in three or more villous sections by using morphometric software (Histolab version 5.2.3; Microvision Instruments). The result was expressed as mean number of labeled nuclei of VT per surface area (80 000 mm 2 ) of placental villus.
Invasion Assays
Invasion assays were performed in 24-well plates containing Matrigel (BD Matrigel Basement Membrane Matrix, with growth factors; Becton Dickinson)-coated polycarbonate membrane (8-lm pore size) invasion chamber inserts (Greiner Bio-One SAS). Cells were cultured at a density of 1 3 10 5 for human primary EVT in serum-free medium in the presence or absence of PIF or 10% FCS. After 48 h, cells were carefully removed from the top side of the insert with a cotton-tipped swab. The lower side of the insert was stained with 4 0 ,6-diamidino-2-phenylindole as described [36] . The numbers of migratory and invasive cells in the lower chamber were determined by counting the stained cells in five randomly selected, nonoverlapping fields at a magnification of 203.
Zymography
The total gelatinase activities of MMP2 and MMP9 were analyzed by zymography. Aliquots of culture media from placental explants (containing 2 lg protein) were resolved under nonreducing conditions on 10% polyacrylamide gels containing 1 mg/ml gelatin (Difco). Gels were washed in 2.5% Triton X-100 for 30 min, incubated overnight at 378C in renaturing buffer (50 mM Tris-HCl pH 7.5, 5 mM CaCl 2 , 150 mM NaCl, and 0.02% sodium azide), stained with Coomassie Brilliant Blue, and destained in methanol/acetic acid (20%/5% v/v). Proteolytic activity was identified as a clear band on a blue background. The images were scanned and quantitative enzyme analysis was carried out using Bio1D Software (Vilbert Lourma).
Quantitative RT-PCR
Total RNA (0.1 lg) was extracted and reverse transcribed as previously described [37] . Quantitative RT-PCR was performed with the primer sets Table 1 and Sybergreen I Master Mix (Roche Diagnostics), using a LightCycler480 instrument from Roche Diagnostics. The second derivative maximum method was used to automatically determine the crossing point (Cp) for individual samples. Three reference genes (ribosomal protein L13A [RPL13A], TATA box binding protein [TBP] , and b-2 microglobulin [B2M]) were chosen as previously described [38] . For each sample, the concentration ratio (target/three reference mRNAs) was calculated using RelQuant software (Roche Diagnostics). Calibration curves were log linear over the quantification range, with a correlation coefficient (r 2 ) . 0.99 and an efficiency ranging from 1.8 to 2. The intra-assay variability of duplicate Cp values never exceeded 0.2 cycles and the interassay variability (coefficient of variation value) ranged from 1% to 5% for the five or seven runs of each transcript. The PCR products were separated on a 2% agarose gel in 90 mM Tris-borate, 2 mM EDTA buffer, pH 8.0, and visualized by GelRed acid nucleic staining and ultraviolet transillumination.
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Statistical Analysis
All values were expressed as mean 6 SEM of 4 to 12 separate experiments. All statistical analysis were performed using a nonparametric paired Wilcoxon test and one-way ANOVA parametric followed by Dunn test.
RESULTS
Localization of PIF in Human Placenta Throughout Gestation
Before investigating PIF effects on human primary EVT, we examined PIF distribution in human placental tissues by immunohistochemistry (IHC). Immunoreactivity to cytokeratin was used to identify CTs, syncytiotrophoblasts (STs), and EVTs. The proto-oncogene product c-erbB2 staining was used to identify EVTs.
First, PIF localization within first-and third-trimester human placentas was studied. An IHC analysis of firsttrimester (4-8 and 12 WG) and third-trimester (30-34 and 38 WG) placental sections revealed that PIF labeling decreased over the course of pregnancy (Figs. 1 and 2 ). More precisely, PIF labeling decreased in placental tissues from 12 to 38 WG. The STs, CTs, and EVTs exhibited strong nuclear and cytoplasmic PIF immunoreactivity in first-trimester placentas
FIG. 4. Characterization of primary EVT. Immunocytochemistry (A), flow cytometry (B)
, and RT-PCR analysis (C) were performed to test EVT cell purity. Primary EVTs isolated from first-trimester placentas were stained with CK7 or HLA-G antibodies for immune-fluorescent detection or without antibody as negative control. Hoechst was used for blue nuclear staining as described in Materials and Methods. CK7 and HLA-G mRNA expressions were measured as described in Materials and Methods. Total RNA was extracted from human primary EVT and analyzed by RT-PCR with the primers described in Table 1 . The results shown are the mean 6 SEM of six separate experiments. **P , 0.01; NS, nonsignificant, Wilcoxon test. (Fig. 1) . In contrast, villous stromal cells were only weakly labeled (Fig. 1) .
PIF PROMOTES HUMAN TROPHOPHOBLAST INVASION
Secondly, in order to characterize the cell types labeled with PIF antibody in human placenta, IHC staining patterns were investigated in serial histological sections of first-trimester placentas (Fig. 3) . In anchoring villi, PIF labeling was intense in STs, CTs, and EVTs, comparable to cytokeratin staining (Fig. 3, A-D) . At the implantation site, we observed a weak cytoplasmic PIF labeling in decidual cells and a strong nuclear and cytoplasmic PIF labeling in EVT (Fig. 3, E and F) . 
FIG. 7.
Effects of PIF on the MMP/TIMP balance. Gelatinase activities in conditioned media from human placental explants (A) and TIMP mRNA expressions from primary EVT (B and C) were measured as described in Materials and Methods. Cells or explants were incubated for 48 h in the absence or presence (50 nM) of PIF. A) The results shown are the mean 6 SEM of eight or nine separate experiments. ***P , 0.005; NS, nonsignificant, Wilcoxon test. B and C) Total RNA was extracted from human primary EVT and analyzed by RT-PCR with the primers described in Table 1 . The results shown are the mean 6 SEM of six to nine separate experiments. *P , 0.05; NS, nonsignificant, Wilcoxon test.
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Effects of PIF on Cell Invasive and Proliferative Capacities
To evaluate the effects of PIF on EVT, we first isolated EVT from first-trimester placentas. Immunocytochemical and flow cytometric analysis of cells showed that the purified EVTs used were greater than 95% positive for HLA-G and CK7 (Fig. 4, A  and B) . Moreover, HLA-G mRNA expression was 10-fold higher in human primary EVT than in primary VT (Fig. 4C) .
Because significant amounts of PIF were found in the EVT, we used Matrigel Transwell invasion assays to investigate the ability of PIF to modify the invasive properties of human EVTs. EVTs were incubated for 48 h with PIF at 10-100 nM. Exposure to 50 and 100 nM PIF was associated with greater EVT invasion (þ108 and þ58%, respectively). However, exposure to 10 or 25 nM PIF was not associated with any significant invasive effect. In our experimental conditions, FCS (10%) was used as a positive control for EVT invasion (Fig. 5) .
In parallel, we used Ki67 immunostaining of first-trimester placental explant to examine the effect of PIF on cell proliferation (Fig. 6 ). The nuclear antigen Ki67 is present throughout all active phases of the cell cycle. This experiment demonstrated that PIF (at either 50 or 100 nM) had no significant effect on cell proliferation. In our experimental conditions, FCS (10%) was used as a positive control for cell proliferation and CT viability.
Given that the maximal proinvasive effect of PIF on EVT was observed at a concentration of 50 nM, the latter dose was used in all subsequent experiments.
Effects of PIF on MMP2 and MMP9 Activities
Because MMP2 and MMP9 are the main MMPs involved in trophoblast invasion, their respective enzyme activities in conditioned media from first-trimester human placental explants were examined with gelatin zymography (Fig. 7A) . MMP9 (but not MMP2) activity was higher (þ59%) after treatment of placental explants with PIF for 48 h.
Effects of PIF on TIMP1 and TIMP2 mRNA Expressions
The mRNA expression levels of MMP inhibitors (including TIMP1 and TIMP2) in the human primary EVT were measured after PIF treatment for 24 or 48 h (Fig. 7, B and C) . As shown in Figure 7B , PIF treatment decreased in a time-dependent manner the TIMP1 mRNA expression in human EVT (À15% after 24 h and À26% after 48 h). In contrast, PIF had no effect on TIMP2 mRNA expression (Fig. 7C) .
Effects of PIF on ITG mRNA Expressions
EVT differentiation and its invasive phenotype acquisition are regulated by switching of ITG expression. The expression of a1 ITG (ITGA1) and av ITG (ITGAV) mRNA, both of which are known to be involved in human EVT invasion, was measured (Fig. 8) . Treatment with PIF for 24 h was associated with a significant positive effect on ITGAV (þ25%) and on ITGA1 (þ32%) ITG mRNA expression (Fig. 8, A and B) . In contrast, PIF treatment during 48 h decreased ITGA1 mRNA expression (À28%) and had no significant effect on ITGAV mRNA expression in human EVT.
Signaling Pathways Involved in Proinvasive Effects of PIF
To gain insight into the molecular mechanisms underlying PIF-induced invasion by human trophoblastic cells, further experiments were performed using selective inhibitors of the MAPK, PI3K, and JAK-STAT signaling pathways (UO126, LY294002, and AG490, respectively). As shown in Figure 9 , the proinvasive effect of PIF was abrogated when any of the MAPK, or PI3K, or JAK-STAT pathways was inhibited. However, invasion by EVT was not altered by incubation with any of these inhibitors when used alone.
DISCUSSION
PIF is produced by viable mammalian embryos at an early stage of development and is detected precociously at the fetomaternal interface [20] .
In the present study, we confirmed that PIF is present in human first-trimester and (to a lesser extent) third-trimester placentas, as previously described [20] . In addition, we completed these observations by establishing, for the first time, that localization of PIF is limited to the two main placental cell types (the ST around the chorionic villi and EVT). Because PIF is also present in the syncytium, it remains Total RNA was extracted from human primary EVT and analyzed by RT-PCR with the primers described in Table 1 . Cells were incubated for 48 h in the absence or presence (50 nM) of PIF. The results shown are mean 6 SEM of seven separate experiments. **P , 0.01; *P , 0.05; NS, nonsignificant, Wilcoxon test.
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to be seen whether PIF affects the human placenta endocrine function.
Once the presence of PIF at the fetomaternal interface was established, we attempted to shed light on the role of PIF in primary human trophoblast cell invasion. Transwell assays clearly demonstrated that PIF promotes the invasive properties of human EVT at 50 and 100 nM with a maximal effect at 50 nM. These PIF concentrations correspond to those found in the maternal circulation (30-100 nM) [28] . It is possible that the decrease of PIF effect at 100 nM is due to the down-regulation of putative PIF binding sites in human trophoblasts.
In the present study, the proinvasive effects of PIF were observed at 50 nM, a much lower concentration than the one used in the HTR-8/SVneo experiments. This difference could be related to the following parameters: 1) EVT could have a higher density of PIF-specific binding sites than the HTR-8/ SVneo trophoblastic cell line and thus would be more sensitive to PIF and/or 2) EVT might express cofactors involved in physiological effects of PIF at higher levels than trophoblastic cell lines. Experiments are currently in progress in our laboratory to identify the PIF cofactors. One putative candidate could be the transcription factor Dlx-3, which was recently described as exerting an essential role in human trophoblast invasion [39] .
It is also demonstrated that the proinvasive effects of PIF were accompanied by activation of the gelatinase activity of MMP9 and a time-dependent repression of TIMP1 expression. It is well established that 1) MMP9 activity plays a major role in trophoblast invasion, 2) TIMP1 is the preferential inhibitor of MMP9 [4] , and 3) MMP9 deficiency causes physiological and placental abnormalities in mice that mimic features of preeclampsia [40] . These findings suggest that MMP/TIMP balance is a part of the mechanism required for PIF to induce trophoblast invasion and that PIF could be implicated in pathologies of pregnancy. Several studies have shown that trophoblast differentiation to an invasive phenotype is also accompanied by temporally and spatially regulated switching of their ITG expression pattern [5] . Herein, it is demonstrated that ITGAV and ITGA1 mRNA expressions were increased after 24 h of PIF treatment. This last result is in accordance with the invasion-promoting role of ITGAV and ITGA1. However, after 48 h of PIF treatment, a decrease for ITGA1 but not ITGAV ITG mRNA expression was observed. Such observations can be explained by a negative feedback regulation of ITG expression to prevent excessive invasion of the maternal endometrium, as described in the tumorigenic process [41] . Last, we demonstrated that PIF did not affect trophoblast proliferation, suggesting that the increase in invasion cannot be explained by an elevated mitogenic response.
Multiple signaling pathways are known to be involved in human trophoblast invasion [12, 42] . To gain insight into molecular mechanisms involved in PIF-induced invasion, the MAPK, PI3K/AKT, and JAK-STAT signaling pathways were investigated in this work. Results suggest that PIF essentially modulates trophoblast invasion via the MAPK, PI3K, and JAK-STAT transduction pathways as described for other proinvasive factors [43, 44] .
Two murine studies have revealed that PIF exerts a protective role in clinically relevant nonpregnant models of type I juvenile diabetes and neuro-inflammation by regulating the production of cytokines such as interleukin 6 (IL6) [25, 26] . A study of human endometrium also has revealed that PIF upregulates proinflammatory cytokines like IL6 [23] . Moreover, IL6 has been described as a potential proinvasive cytokine in human CTs [45, 46] . Hence, one cannot rule out a mechanism in which PIF stimulates the EVT invasive capacity by directly and/or indirectly modulating placental secretion of IL6.
In conclusion, data presented here show that PIF promotes human trophoblast invasion by regulating MMP9/TIMP1 balance and the ITG expression pattern. PIF seems to exert this proinvasive effect through multiple cell signaling pathways. As inadequate invasion has been reported in the placentas of women with intrauterine growth retardation and/ or preeclampsia [47, 48] , the present findings strongly suggest that this peptide should be investigated with the prospective of being used to prevent or treat these pregnancy complications. MOINDJIE ET AL.
